Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 3Phase 1 3Phase NA 1Phase 4 1Phase 3 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Breast Neoplasms 60Neoplasms 24Prostatic Neoplasms 21Multiple Myeloma 17Carcinoma, Non-Small-Cell Lung 15Carcinoma, Hepatocellular 15Stomach Neoplasms 11Papillomavirus Infections 11Lung Neoplasms 11Colorectal Neoplasms 10Melanoma 9Pain, Postoperative 7Neoplasm Metastasis 7Leukemia, Myeloid, Acute 7Waldenstrom Macroglobulinemia 6Lymphoma, Non-Hodgkin 6Leiomyoma 6Hematologic Neoplasms 6Brain Neoplasms 6Uterine Cervical Neoplasms 5Smoking Cessation 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Polycystic Ovary Syndrome 5Pain 5Lymphoma 5Glioma 5Carcinoma, Renal Cell 5Venous Thromboembolism 4Urinary Bladder Neoplasms 4Tobacco Use Disorder 4

Interventions

obinutuzumab 1acalabrutinib 1Rituximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Lymphatic Diseases × 1 year × Clear all
NCT06651970 2026-05-18

Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure

AstraZeneca

Phase 4 Recruiting
60 enrolled
LymphoidOther hematologic neoplasm

Heart Failure, Lymphatic Diseases, Leukemia, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡